Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing (Q34389432)

1 August 2017

title

Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing (English)

1 reference

1 August 2017

1 reference

Michelle Whirl-Carrillo

3

object named as

M Whirl-Carrillo

1 reference

1 August 2017

K E Caudle

1

1 reference

1 August 2017

A E Rettie

2

1 reference

1 August 2017

L H Smith

4

1 reference

1 August 2017

S Mintzer

5

1 reference

1 August 2017

M T M Lee

6

1 reference

1 August 2017

T E Klein

7

1 reference

1 August 2017

J T Callaghan

8

1 reference

1 August 2017

Clinical Pharmacogenetics Implementation Consortium

9

1 reference

1 August 2017

language of work or name

English

0 references

publication date

6 August 2014

1 reference

Clinical Pharmacology & Therapeutics

1 August 2017

published in

1 reference

1 August 2017

volume

96

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

542-548

1 reference

Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.

1 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Pharmacogenomics knowledge for personalized medicine

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

PharmGKB summary: phenytoin pathway

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Phenytoin-induced Stevens-Johnson syndrome with negative HLA-B*1502 allele in mainland China: two cases

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Oxcarbazepine-induced Stevens-Johnson syndrome: a case report

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Phenytoin hepatotoxicity: a case report and review

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

The role of CYP2C9 polymorphisms in phenytoin-related cerebellar atrophy

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Severe phenytoin toxicity in a CYP2C9*3*3 homozygous mutant from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Developmental expression of human hepatic CYP2C9 and CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Letter: HLA B*1502 allele association with oxcarbamazepine-induced skin reactions in epilepsy patient from India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Oxcarbazepine-induced Stevens-Johnson syndrome in a patient with HLA-B*1502 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Severe phenytoin intoxication in a subject homozygous for CYP2C9*3.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4206662

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

27 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2014.159

Decreased capacity to metabolize diphenylhydantoin in a patient with hypersensitivity to warfarin

21 January 2018

1 reference

12 December 2020

Immunoquantification of epoxide hydrolase and cytochrome P-450 isozymes in fetal and adult human liver microsomes

1 reference

12 December 2020

Phenytoin age-dose-concentration relationship in children

1 reference

12 December 2020

Effects of polymorphisms in six candidate genes on phenytoin maintenance therapy in Han Chinese patients

1 reference

12 December 2020

Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore

1 reference

12 December 2020

Identifiers

DOI

10.1038/CLPT.2014.159

1 reference

1 August 2017

1 reference

1 August 2017

1 reference